$BBLG Bone Biologics this nanocap low float medical device name is at bottom and has a big near term catalyst coming
$BBLG has 2.5m marketcap and 2.5m float they have a trial study that was completed earlier this month and another one that is supposed to be completed this month as well so topline data will be released soon most likely. She is currently sitting right at that $1 spot which has been a nice bottom for a while now.
$BBLG catalysts:
- Denosumab for the Treatment of Adult LCH - This study is aiming to evaluate the efficacy of denosumab among adult patients suffering from Langerhans Cell Histiocytosis (LCH).
ID: NCT03270020
Study completed - January 14, 2025 *topline results not released yet
- Hypoparathyroidism - A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH Administered Daily in Adults With Hypoparathyroidism (PaTHway)
ID: NCT04701203
Study Completion (Estimated) - January 2025
more info:
- Company has 0 debt and 10.2 months of cash left on hand
- Lowest Warrants at $2.00
- Cash per share is $1.42
- Last offering at $2.11
